Vascular News and Research

RSS

BioTime obtains license from Wistar Institute for technology related to SP100 gene

BioTime, Inc. today announced that it has obtained an exclusive license from The Wistar Institute in Philadelphia, PA for technology related to a gene designated as SP100.

25 Jan 2012

One-year results from Covidien's EverFlex stent trial on P.A.D.

Covidien, a leading global provider of healthcare products, today announced that one-year results on the use of its EverFlex stent for superficial femoral artery stenting were presented here during the International Symposium on Endovascular Therapy (ISET) Conference.

25 Jan 2012

Enrollment complete in Medtronic's CoreValve U.S. Trial for severe aortic stenosis

Medtronic, Inc. today announced it has completed patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The company also received approval from the U.S. Food and Drug Administration (FDA) for an extended investigation to continue enrolling extreme risk patients under a Continued Access Study protocol.

From Medtronic 25 Jan 2012

Link between high fructose intake and cardiovascular risk in adolescents

Evidence of cardiovascular disease and diabetes risk is present in the blood of adolescents who consume a lot of fructose, a scenario that worsens in the face of excess belly fat, researchers report.

25 Jan 2012

Study reports Tennessee collaborative improves quality of surgical care

A new study published online today in the Journal of the American College of Surgeons finds hospitals participating in a regional collaborative of the American College of Surgeon's National Surgical Quality Improvement Program (ACS NSQIP-), achieved substantial improvements in surgical outcomes, such as reducing the rates of acute renal failure and surgical site infections.

24 Jan 2012

Covidien releases results of TurboHawk and SpiderFX combination study on P.A.D.

Covidien, a leading global provider of healthcare products, today released the results of the DEFINITIVE Ca++ study.

24 Jan 2012

Possible link between vascular lesions and Alzheimer's disease

Approximately 20 percent of all stroke survivors will develop cognitive problems later in life, including vascular dementia. Experts with the Methodist Neurological Institute in Houston say recent research showing a possible link between vascular lesions and Alzheimer's disease is yet another reason to be more vigilant in our efforts to prevent a stroke.

24 Jan 2012

Researchers uncover 13 novel genetic loci linked with onset of menopause

An international team of researchers from the Boston University Schools of Public Health and Medicine and other institutions has uncovered 13 genetic loci, linked to immune function and DNA repair, that are factors in the age of onset of menopause.

24 Jan 2012

Sex declared safe for heart patients

A doctors’ group on Thursday suggested that sex may be safe for most heart patients. The American Heart Association added that having sex only slightly raises the chance for a heart attack. And that’s true for people with and without heart disease. Despite the higher risk for a heart patient to have a second attack, there’s no evidence that they have more sex-related heart attacks than people without cardiac disease. The updated advice was released online Thursday in the heart association journal, Circulation.

22 Jan 2012

Study shows 50% reduction in blindness and severe visual loss in Denmark

Age-related macular degeneration (AMD) is the most frequent cause of blindness in the Western World. A report from the University of Copenhagen and Glostrup Hospital in Denmark published today shows the number of new cases of blindness and severe visual loss in Denmark has been halved during the last ten years.

20 Jan 2012

Minimally invasive renal denervation performed for the first time in Canada

Doctors at the Peter Munk Cardiac Centre today performed a minimally invasive surgical procedure to treat high blood pressure, called renal denervation, for the first time in Canada.

18 Jan 2012

Peter Munk Cardiac Centre doctors perform renal denervation in first Canadian patient

Doctors at the Peter Munk Cardiac Centre today performed a minimally invasive surgical procedure to treat high blood pressure, called renal denervation, for the first time in Canada. The procedure can significantly reduce high blood pressure in patients who cannot effectively treat their hypertension through drugs. These patients, numbering approximately 250,000 Canadians, have to endure an especially high risk of heart attacks and stroke, which continues to kill thousands of Canadians every year.

18 Jan 2012

Ethanol, nonalcoholic compounds in red wine may reduce risk of vascular disease

Observational epidemiologic studies relating wine and alcohol to health all suffer from the fact that they, of necessity, compare people who prefer certain beverages, but not the beverages themselves. While there have been many intervention trials in animals, randomized trials in humans are less common. Randomized crossover trials, in which each subject receives all interventions in sequence, can be especially important as they tend to avoid baseline differences among subjects and can detect effects of different interventions with smaller numbers of subjects.

18 Jan 2012

US BioDesign introduces new cardiovascular biomaterials business unit

US BioDesign announced today the launch of its cardiovascular biomaterials business segment. This portion of US BioDesign will be responsible for the research, analysis and production of products and services in the cardiovascular device area.

18 Jan 2012

VeriTeQ acquires PositiveID's VeriChip and Health Link web-based PHR

VeriTeQ Acquisition Corporation, a marketer of implantable, radio frequency identification technologies for patient identification and sensor applications, announced today it has acquired the VeriChip implantable microchip and related technologies, and Health Link personal health record from PositiveID Corporation.

18 Jan 2012

Medtronic announces CE mark and launch of Endurant II AAA Stent Graft System

Medtronic Inc. today announced the CE mark and international launch of the Endurant II AAA Stent Graft System, which meaningfully expands the options physicians outside the United States have to treat patients with abdominal aortic aneurysms through a minimally invasive technique called endovascular aortic repair.

From Medtronic 17 Jan 2012

No statistical difference between IO and IV infusion in therapeutic hypothermia

The results of a study conducted by Vidacare Corporation comparing whether Intraosseous (IO) vascular access may be used to infuse chilled saline as effectively as peripheral intravenous (IV) access to achieve therapeutic hypothermia found no statistical difference between the two routes.

17 Jan 2012

Angioplasty improves quality of life in MS patients

Although using angioplasty to treat multiple sclerosis (MS) is highly controversial, sufferers often insist it helps - in some cases dramatically, such as allowing them to walk without a cane. Patients with less severe MS also reported additional quality of life improvements, such as being able to talk more clearly, after having treatment to open blocked blood vessels in the chest and neck, according to research being presented at the 24th annual International Symposium on Endovascular Therapy.

17 Jan 2012

Positive outcomes from Boston Scientific's Epic Stent trial on iliac artery disease

Boston Scientific Corporation reports nine-month clinical endpoint data from its ORION trial, demonstrating excellent outcomes for the Company's Epic Self-Expanding Nitinol Stent System in patients with iliac artery disease, a form of peripheral artery disease associated with severe leg pain caused by insufficient blood flow.

16 Jan 2012

Smart injectable nanotherapeutics could improve treatment for Type I diabetes

A research collaboration between the Wyss Institute for Biologically Inspired Engineering at Harvard University and Children's Hospital Boston has developed "smart" injectable nanotherapeutics that can be programmed to selectively deliver drugs to the cells of the pancreas. Although this nanotechnology will need significant additional testing and development before being ready for clinical use, it could potentially improve treatment for Type I diabetes by increasing therapeutic efficacy and reducing side effects.

13 Jan 2012